Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellest Lenses and Low-concentration Atropine for Myopia Control
NCT06344429Recruiting
- Sponsor
- Essilor
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of atropine in myopia (3 arms), sponsored by Essilor. Primary endpoint: Spherical Equivalent Refraction Power at 12 months. Started Aug 2023; status: recruiting.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on NCT06344429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344429.